{"disease":{"id":"ewing-family-of-tumors","name":"ewing family of tumors"},"drugs":{"marketed":[{"drug_id":"busilvex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"busulfex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03496402","title":"Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT03542097","title":"Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT02159443","title":"Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody","phase":"","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01505569","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03495921","title":"A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Gradalis, Inc.","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}